MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Losartan potassium

CAS No. : 124750-99-8

MCE 站：Losartan potassium

产品活性：Losartan potassium (DuP-753 potassium) 是血管紧张素 II 受体 1 型 (AT1)拮抗剂，与血管紧张素 II 与 AT1 的结合竞争，IC₅₀ 为 20 nM。

研究领域：GPCR/G Protein

作用靶点：Angiotensin Receptor

In Vitro: Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC₅₀) is 20 nM. Losartan (40?μM) affects I_SC but prevents the effect of ANGII on I_SC. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone.

In Vivo: Losartan (0.6 g/L, p.o.) -treated Fbn1^C1039G/+ mice show a reduction in distal airspace caliber relative to placebo-treated Fbn1^C1039G/+ animals. The doses of losartan and propranolol are titrated to achieve comparable hemodynamic effects. Analysis of pSmad2 nuclear staining reveals that losartan antagonizes TGF-β signaling in the aortic wall of Fbn1^C1039G/+ mice. Losartan can improve disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics. Losartan (10 mg/kg, intraarterial injection) increases blood angiotensin levels four- to sixfold. Losartan (10 mg/kg, i.p.) increases plasma renin levels 100-fold; plasma angiotensinogen levels decreases to 24% of control; and plasma aldosterone levels are unchanged.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Endocrinology Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Angiotensin II human  |  Losartan  |  A 779  |  Telmisartan  |  PD 123319 ditrifluoroacetate  |  AVE 0991  |  Valsartan  |  Olmesartan  |  Tranilast  |  YS-49  |  Irbesartan  |  Candesartan  |  CGP-42112  |  Olodanrigan  |  Sparsentan  |  C-Type Natriuretic Peptide (CNP) (1-22), human  |  Azilsartan medoxomil  |  Angiotensin II 5-valine  |  Eprosartan mesylate  |  Angiotensin (1-7) (acetate)  |  Fimasartan  |  Tasosartan  |  Angiotensin II (3-8), human TFA  |  Brain Natriuretic Peptide (1-32), rat acetate

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。